title: Is microbubble-enhanced ultrasonography sufficient for assessment of response to percutaneous treatment in patients with early hepatocellular carcinoma?
abstract: The objective of this study was to assess the efficacy of contrast-enhanced ultrasonography (CEUS) with SonoVue to evaluate the response to percutaneous treatment (ethanol injection/radiofrequency) of hepatocellular carcinoma in comparison with spiral computed tomography (CT) immediately and 1 month after treatment. Forty-one consecutive cirrhotic patients with early stage tumor (not suitable for resection) were included. Spiral CT and CEUS were performed in all patients before treatment, in the following 24 h, and 1 month later. The results of each examination were compared with the 1-month spiral CT, considered the gold standard technique. The 24-h CEUS and the 24-h spiral CT sensitivity to detect residual disease were 27% and 20%, respectively. The 24-h CEUS and the 24-h spiral CT positive predictive value of persistent vascularization detection were 75% and 66%, respectively. The 1-month CEUS detected partial responses in ten out of 11 cases (91% sensitivity, 97% specificity, 95% accuracy). Spiral CT and CEUS performed in the 24 h following treatment are slightly useful to evaluate therapeutic efficacy. The 1-month CEUS has a high diagnostic accuracy compared with spiral-CT in the usual assessment of percutaneous treatment response.
authors.affiliation: Diagnosis Imaging Center, IDIBAPS, Hospital Clínic, University of Barcelona, Barcelona, Spain. rvilana@clinic.ub.es
authors.forename: R
authors.initials: R
authors.lastname: Vilana
authors.forename: L
authors.initials: L
authors.lastname: Bianchi
authors.forename: M
authors.initials: M
authors.lastname: Varela
authors.forename: C
authors.initials: C
authors.lastname: Nicolau
authors.forename: M
authors.initials: M
authors.lastname: Sánchez
authors.forename: C
authors.initials: C
authors.lastname: Ayuso
authors.forename: M
authors.initials: M
authors.lastname: García
authors.forename: M
authors.initials: M
authors.lastname: Sala
authors.forename: J M
authors.initials: JM
authors.lastname: Llovet
authors.forename: J
authors.initials: J
authors.lastname: Bruix
authors.forename: C
authors.initials: C
authors.lastname: Bru
mesh_terms: D000279:Administration, Cutaneous; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000601:surgery; D017115:Catheter Ablation; D002492:Central Nervous System Depressants / Q000627:therapeutic use; D000431:Ethanol / Q000627:therapeutic use; D005189:False Positive Reactions; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007089:Image Enhancement; D007091:Image Processing, Computer-Assisted; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology* / Q000601:surgery; D008297:Male; D045423:Microbubbles; D008875:Middle Aged; D009367:Neoplasm Staging; D010743:Phospholipids / Q000008:administration & dosage / Q000378:metabolism; D011446:Prospective Studies; D012680:Sensitivity and Specificity; D013459:Sulfur Hexafluoride / Q000008:administration & dosage / Q000378:metabolism; D013997:Time Factors; D036542:Tomography, Spiral Computed; D016896:Treatment Outcome; D047368:Tumor Burden; D018084:Ultrasonography, Interventional / Q000379:methods*
chemical_list: D002492:Central Nervous System Depressants; D010743:Phospholipids; C420843:contrast agent BR1; D000431:Ethanol; D013459:Sulfur Hexafluoride